Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients

International Journal of Cardiology

Volumn 101, Issue 1, 2005, Pages 9-17

  Launay Vacher, Vincent ^a   Izzedine, Hassane ^a   Deray, Gilbert ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Cyclosporine; Drug dosage adjustment; Drug drug interaction; HMG CoA reductase inhibitors; Renal insufficiency

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CYCLOSPORIN; DRUG METABOLITE; FLUINDOSTATIN; HYDROXYACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; SQ 31906; SQ 31945;

CLINICAL TRIAL; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DYSLIPIDEMIA; HUMAN; KIDNEY FAILURE; KIDNEY GRAFT; MUSCLE TOXICITY; MYALGIA; MYOPATHY; MYOSITIS; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RECIPIENT; RENAL PROTECTION; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT;

EID: 18144386137     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2004.04.005     Document Type: Review

References (103)

1. V. Launay-Vacher, T. Storme, H. Izzedine, and G. Deray Pharmacokinetic changes in renal failure Presse Med. 30 12 2001 597 604
2. G.C. Yee Recent advances in cyclosporine pharmacokinetics Pharmacotherapy 11 1991 130S 134S
3. G. Li, G. Treiber, J. Meinshausen, J. Wolf, J. Werringloer, and U. Klotz Is cyclosporin A an inhibitor of drug metabolism? Br. J. Clin. Pharmacol. 30 1 1990 71 77
4. S.M. Moochhala, and K.W. Renton Inhibition of hepatic microsomal drug metabolism by the immunosuppressive agent cyclosporin A Biochem. Pharmacol. 35 9 1986 1499 1503
5. A. Asberg Interactions between cyclosporin and lipid-lowering drugs. Implications for organ transplant recipients Drugs 63 2003 367 378
6. D.M. Gibson, B.B. Yang, R.B. Abel, R.A. Blum, M. Horton, and R.H. Stern Effects of hepatic and renal impairment on pharmacokinetics (PK) and pharmacodynamics (PD) of atorvastatin Pharm. Res. 13 Suppl. 9 1996 S428
7. A.S. Kearney, L.F. Crawford, S.C. Mehta, and G.W. Radebaugh The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981 Pharm. Res. 10 1993 1461 1465
8. A.E. Black, R.N. Hayes, B.D. Roth, P. Woo, and T.F. Woolf Metabolism and excretion of atorvastatin in rats and dogs Drug Metab. Dispos. 27 8 1999 916 923
9. T. Kantola, K.T. Kivisto, and P.J. Neuvonen Effect of itraconazole on the pharmacokinetics of atorvastatin Clin. Pharmacol. Ther. 64 1 1998 58 65
10. R.H. Stern, M. Horton, S. Moore, R.B. Abel, and S.C. Olson Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin J. Clin. Pharmacol. 37 1997 816 819
11. R.L. Lins, K.E. Matthys, G.A. Verpooten, P.C. Peeters, M. Dratwa, and J.C. Stolear Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients Nephrol. Dial. Transplant. 18 2003 967 976
12. G. Hufnagel, C. Michel, F. Vrtovsnik, G. Queffeulou, N. Kossari, and F. Mignon Effects of atorvastatin in uraemic patients on peritoneal dialysis Nephrol. Dial. Transplant. 15 2000 684 688
13. K.P. Harris, D.C. Wheeler, and C.C. Chong A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD Kidney Int. 61 2002 1469 1474
14. R.L. Lins, K.E. Matthys, G.A. Verpooten, P.C. Peeters, M. Dratwa, and J.C. Stolear Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic patients Nephrol. Dial. Transplant. 18 5 2003 967 976
15. W. Jacobsen, B. Kuhn, A. Soldner, G. Kirchner, K.F. Sewing, and P.A. Kollman Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin Drug Metab. Dispos. 28 11 2000 1369 1378
16. A.E. Black, M.W. Sinz, R.N. Hayes, and T.F. Woolf Metabolism and excretion studies in mouse after single and multiple oral doses of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin Drug Metab. Dispos. 26 8 1998 755 763
17. A. Asberg, A. Hartmann, E. Fjeldsa, S. Bergan, and H. Holdaas Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients Am. J. Transplant. 1 4 2001 382 386
18. H.C. Maltz, D.L. Balog, and J.S. Cheigh Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine Ann. Pharmacother. 33 11 1999 1176 1179
19. P.J. Taylor, P.A. Kubler, S.V. Lynch, J. Allen, M. Butler, and P.I. Pillans Effect of atorvastatin on cyclosporin pharmacokinetics in liver transplant recipients Ann. Pharmacother. 38 2 2004 205 208
20. R.I. Levy, A.J. Troendle, and J.M. Fattu A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin Circulation 87 Suppl. 4 1993 III45 III53
21. M.H. Davidson Fluvastatin long-term extension trial (FLUENT): summary of efficacy and safety Am. J. Med. 96 1994 S41 S44
22. J.G. Dain, E. Fu, J. Gorski, J. Nicoletti, and T.J. Scallen Biotransformation of fluvastatin sodium in humans Drug Metab. Dispos. 21 4 1993 567 572
23. H.T. Smith, L.A. Jokubaitis, A.J. Troendle, D.S. Hwang, and W.T. Robinson Pharmacokinetics of fluvastatin and specific drug interactions Am. J. Hypertens. 6 11 Pt. 2 1993 375S 382S
24. H.D. Langtry, and A. Markham Fluvastatin: a review of its use in lipid disorders Drugs 57 4 1999 583 606
25. C.J. Lintott, R.S. Scott, J.M. Bremer, and B.I. Shand Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency Am. J. Cardiol. 76 1995 87A 101A
26. O. Samuelsson, P.O. Attman, C. Knight-Gibson, H. Mulec, L. Weiss, and P. Alaupovic Fluvasttain improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency Am. J. Kidney Dis. 39 2002 67 75
27. S. Appel-Dingemanse, T. Smith, and M. Merz Pharmacokinetics of fluvastatin in subjects with renal impairment and nephrotic syndrome J. Clin. Pharmacol. 42 3 2002 312 318
28. S. Appel, and J. Dingemanse Clinical pharmacokinetics of fluvastatin with reference to other HMG-CoA reductase inhibitors Drugs Today 32 1996 39 55
29. H. Lennernas, and G. Fager Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences Clin. Pharmacokinet. 32 1997 403 425
30. V. Fischer, L. Johanson, F. Heitz, R. Tullman, E. Graham, and J.P. Baldeck The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions Drug Metab. Dispos. 27 3 1999 410 416
31. C. Transon, T. Leemann, N. Vogt, and P. Dayer In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin Clin. Pharmacol. Ther. 58 4 1995 412 417
32. H. Holdaas, A. Hartmann, J. Strenstrom, K.J. Dahl, M. Borege, and P. Pfister Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine Am. J. Cardiol. 76 1995 102A 106A
33. P. Railoa, M. Manzo, and A. Saggese Interaction of cyclosporine and fluvastatin with and without niacin in renal transplant patients with dyslipoproteinemia J. Am. Soc. Nephrol. 7 1996 1920
34. P.K. Li, T.W. Mak, A.Y. Wang, Y.T. Lee, C.B. Leung, and S.F. Lui The interaction of fluvastatin and cyclosporin A in renal transplant patients Int. J. Clin. Pharmacol. Ther. 33 4 1995 246 248
35. P.K. Li, T.W. Mak, T.H. Chan, A. Wang, C.W. Lam, and K.N. Lai Effect of fluvastatin on lipoprotein profiles in treating renal transplant recipients with dyslipoproteinemia Transplantation 60 7 1995 652 656
36. R. Goldberg, and D. Roth Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine Transplantation 62 11 1996 1559 1564
37. A. Jardine, and H. Holdaas Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience J. Clin. Pharm. Ther. 24 6 1999 397 408
38. Y.C. Schrama, R.J. Hene, N. de Jonge, J.A. Joles, H.J. Van Rijn, and D.R. Bar Efficacy and muscle safety of fluvastatin in cyclosporine-treated cardiac and renal transplant recipients: an exercise provocation test Transplantation 66 9 1998 1175 1181
39. R.B. Goldberg, and D. Roth A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine Am. J. Cardiol. 76 2 1995 107A 109A
40. J.W. Park, R. Siekmeier, P. Lattke, M. Merz, C. Mix, and S. Schuler Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A J. Cardiovasc. Pharmacol. Ther. 6 4 2001 351 361
41. H. Holdaas, A.G. Jardine, D.C. Wheeler, I.B. Brekke, P.J. Conlon, and B. Fellstrom Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial Kidney Int. 60 5 2001 1990 1997
42. H. Holdaas on behalf of the Assessment of LEscol in Renal Transplantation (ALERT) study investigators Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial Lancet 361 2003 2024 2031
43. W. Jacobsen, G. Kirchner, K. Hallensleben, L. Mancinelli, M. Deters, and I. Hackbarth Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver Drug Metab. Dispos. 27 2 1999 173 179
44. H.Y. Pan, A.R. DeVault, B.J. Swites, D. Whigan, E. Ivashkiv, and D.A. Willard Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia Clin. Pharmacol. Ther. 48 2 1990 201 207
45. J.A.V. Quion, and P.H. Jones Clinical pharmacokinetics of pravastatin Clin. Pharmacokinet. 27 1994 94 103
46. S.M. Singhvi, H.Y. Pan, R.A. Morrison, and D.A. Willard Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects Br. J. Clin. Pharmacol. 29 1990 239 243
47. H.Y. Pan, A.R. DeVault, and D. Wang-Iverson Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin J. Clin. Pharmacol. 30 1990 1128 1135
48. C.E. Halstenson, J. Triscari, A. DeVault, B. Shapiro, W. Keane, and H. Pan Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment J. Clin. Pharmacol. 32 2 1992 124 132
49. T.W.B. Gehr, D.A. Sica, P.H. Slugg, J.L. Hammet, R. Raymond, and N.F. Ford The pharmacokinetics of pravastatin in patients on chronic hemodialysis Eur. J. Clin. Pharmacol. 53 1997 117 121
50. H. Izzedine, V. Launay-Vacher, A. Baumelou, and G. Deray An appraisal of antiretroviral drugs in hemodialysis Kidney Int. 60 3 2001 821 830
51. Y. Nishizawa, T. Shoji, M. Emoto, K. Kawasaki, T. Konishi, and T. Tabata Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients Clin. Nephrol. 43 4 1995 268 277
52. M.B. Regazzi, I. Iacona, C. Campana, V. Raddato, C. Lesi, and G. Perani Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients Transplant. Proc. 25 4 1993 2732 2734
53. V. Kliem, C. Wanner, T. Eisenhauer, C.J. Olbricht, R. Doll, and M. Boddaert Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine Transplant. Proc. 28 6 1996 3126 3128
54. J.A. Rodriguez, M.G. Crespo-Leiro, M.J. Paniagua, J.J. Cuenca, L.F. Hermida, and A. Juffe Rhabdomyolysis in heart transplant patients on HMG-CoA reductase inhibitors and cyclosporine Transplant. Proc. 31 6 1999 2522 2523
55. M. Hedman, P.J. Neuvonen, M. Neuvonen, C. Holmberg, and M. Antikainen Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression Clin. Pharmacol. Ther. 75 1 2004 101 109
56. A.M. Castelao, J.M. Grinyo, M.J. Castineiras, C. Fiol, S. Gilvernet, and D. Seron Effect of pravastatin in the treatment of hypercholesterolemia after renal transplantation under cyclosporine and prednisone Transplant. Proc. 27 4 1995 2217 2220
57. M.A. Omar, and J.P. Wilson FDA adverse event reports on statin-associated rhabdomyolysis Ann. Pharmacother. 36 2 2002 288 295
58. N. Yoshimura, Y. Ohmori, T. Tsuji, and T. Oka Effect of pravastatin on renal transplant recipients treated with cyclosporine-4-year follow-up Transplant. Proc. 26 5 1994 2632 2633
59. N. Yoshimura, T. Oka, M. Okamoto, and Y. Ohmori The effects of pravastatin on hyperlipidemia in renal transplant recipients Transplantation 53 1 1992 94 99
60. H. Schuster Rosuvastatin-a highly effective new 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10-40 mg doses in dyslipidemic patients Cardiology 99 3 2003 126 139
61. H.B. Brewer Jr. Benefit-risk assessment of rosuvastatin 10-40 mg Am. J. Cardiol. 92 4B 2003 23K 29K
62. M.H. Davidson Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia Expert Opin. Invest. Drugs 11 1 2002 125 141
63. F. McTaggart, L. Buckett, R. Davidson, G. Holdgate, A. McCormick, and D. Schneck Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor Am. J. Cardiol. 87 Suppl. 2001 28B 32B
64. Product Information: Crestor(R), rosuvastatin calcium tablets. Astra Zeneca Pharmaceuticals, Wilmington, DE (PI issued 8/2003) reviewed 8/2003.
65. C.I. Carswell, G.L. Plosker, and B. Jarvis Rosuvastatin Drugs 62 14 2002 2086 2087
66. K.J. Cooper, P.D. Martin, A.L. Dane, M.J. Warwick, D.W. Schneck, and M.V. Cantarini The effect of fluconazole on the pharmacokinetics of rosuvastatin Eur. J. Clin. Pharmacol. 58 8 2002 527 5231
67. K.J. Cooper, P.D. Martin, A.L. Dane, M.J. Warwick, A. Raza, and D.W. Schneck The effect of erythromycin on the pharmacokinetics of rosuvastatin Eur. J. Clin. Pharmacol. 59 1 2003 51 56
68. K.J. Cooper, P.D. Martin, A.L. Dane, M.J. Warwick, D.W. Schneck, and M.V. Cantarini Effect of itraconazole on the pharmacokinetics of rosuvastatin Clin. Pharmacol. Ther. 73 4 2003 322 329
69. K.J. Cooper, P.D. Martin, A.L. Dane, M.J. Warwick, A. Raza, and D.W. Schneck Lack of effect of ketoconazole on the pharmacokientics of rosuvastatin in healthy subjects Br. J. Clin. Pharmacol. 55 1 2003 94 99
70. K. Nezasa, K. Higaki, T. Matsumura, K. Inazawa, H. Hasegawa, and M. Nakano Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin Drug Metab. Dispos. 30 11 2002 1158 1163
71. K. Nezasa, K. Higaki, M. Takeuchi, M. Nakano, and M. Koike Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin Xenobiotica 33 4 2003 379 388
72. V.F. Mauro Clinical pharmacokinetics and practical applications of simvastatin Clin. Pharmacokinet. 24 3 1993 195 202
73. F. Fiorini, E. Patrone, and A. Castelluccio Clinical investigation on the hypolipidemic effect of simvastatin versus probucol in hemodialysis patients Clin. Ther. 145 9 1994 213 217
74. R.J. Walker, W.H. Sutherland, H.L. Walker, S. MacMahon, and R.A. Robson Effect of treatment with simvastatin on serum cholesteryl ester transfer in patients on dialysis. Perfect Study Collaborative Group Nephrol. Dial. Transplant. 12 1 1997 87 92
75. R. Robson, J. Collins, R. Johnson, R. Kitching, M. Searle, and R. Walker Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis. The Perfect Study Collaborative Group J. Nephrol. 10 1 1997 33 40
76. O. Nishikawa, M. Mune, M. Miyano, T. Nishide, I. Nishide, and A. Maeda Effect of simvastatin on the lipid profile of hemodialysis patients Kidney Int. Suppl. 71 1999 S219 S221
77. D. Saltissi, C. Morgan, R.J. Rigby, and J. Westhuyzen Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis Am. J. Kidney Dis. 39 2 2002 283 290
78. J.W. Chang, W.S. Yang, W.K. Min, S.K. Lee, J.S. Park, and S.B. Kim Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients Am. J. Kidney Dis. 39 6 2002 1213 1217
79. T. Prueksaritanont, L.M. Gorham, B. Ma, L. Liu, X. Yu, and J.J. Zhao In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s Drug Metab. Dispos. 25 10 1997 1191 1199
80. L. Gullestad, K.P. Nordal, K.J. Berg, H. Cheng, M.S. Schwartz, and S. Simonsen Interaction between lovastatin and cyclosporine A after heart and kidney transplantation Transplant. Proc. 31 5 1999 2163 2165
81. I. Hermida Lazcano, P. Revillo Pinilla, C. Nerin Sanchez, I. Lechuga Duran, and J. Fernandez Lopez Rhabdomyolysis in a patient treated with lovastatin and cyclosporine Ann. Med. Interne 14 9 1997 488
82. C. Olbricht, C. Wanner, T. Eisenhauer, V. Kliem, R. Doll, and M. Boddaert Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses Clin. Pharmacol. Ther. 62 3 1997 311 321
83. J. Bae, J.A. Jarcho, M.D. Denton, and C.C. Magee Statin specific toxicity in organ transplant recipients: case report and review of the literature J. Nephrol. 15 3 2002 317 319
84. M. Kusus, D.D. Stapleton, J.J. Lertora, E.E. Simon, and A.W. Dreisbach Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions Am. J. Med. Sci. 320 6 2000 394 397
85. C. Campana, I. Iacona, M.B. Regazzi, A. Gavazzi, G. Perani, and V. Raddato Efficacy and pharmacokinetics of simvastatin in heart transplant recipients Ann. Pharmacother. 29 3 1995 235 239
86. M. Barbir, M. Rose, S. Kushwaha, S. Akl, A. Mitchell, and M. Yacoub Low-dose simvastatin for the treatment of hypercholesterolaemia in recipients of cardiac transplantation Int. J. Cardiol. 33 2 1991 241 246
87. W.J. Weise, and C.J. Possidente Fatal rhabdomyolysis associated with simvastatin in a renal transplant patient Am. J. Med. 108 4 2000 351 352
88. C. Meier, C. Stey, T. Brack, M. Maggiorini, B. Risti, and S. Krahenbuhl Rhabdomyolysis in patients treated with simvastatin and cyclosporin: role of the hepatic cytochrome P450 enzyme system activity Schweiz. Med. Wochenschr. 125 27-28 1995 1342 1346
89. M. Arnadottir, L.O. Eriksson, H. Thysell, and J.D. Karkas Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin Nephron 65 3 1993 410 413
90. E. Cohen, M.R. Kramer, C. Maoz, D. Ben-Dayan, and M. Garty Cyclosporin drug-interaction-induced rhabdomyolysis. A report of two cases in lung transplant recipients Transplantation 70 1 2000 119 122
91. M. Arnadottir, L.O. Eriksson, J.I. Germershausen, and H. Thysell Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients Nephron 68 1 1994 57 62
92. J. Vanhaecke, J. Van Cleemput, J. Van Lierde, W. Daenen, and H. De Geest Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine Transplantation 58 1 1994 42 45
93. E. Wanf, C.N. Casciano, R.P. Clement, and W.W. Jonhson HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein Pharm. Res. 18 6 2001 800 806
94. J. Dimitroulakos, and H. Yeger HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-glycoprotein-expressing cells Nat. Med. 2 3 1996 326 333
95. T. Tokui, D. Nakai, R. Nakagomi, H. Yawo, T. Abe, and Y. Sugiyama Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, OATP2 Pharm. Res. 16 6 1999 904 908
96. D. Nakai, R. Nakagomi, Y. Furuta, T. Tokui, T. Abe, and T. Ikeda Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes J. Pharmacol. Exp. Ther. 297 2001 861 867
97. B. Hsiang, Y. Zhu, Z. Wang, Y. Wu, V. Sasseville, and W.P. Yang A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters J. Biol. Chem. 274 52 1999 37161 37168
98. H. Lennernas Clinical pharmacokinetics of atorvastatin Clin. Pharmacokinet. 42 13 2003 1141 1160
99. Y. Liu, L. Huang, T. Hoffman, M. Gosland, and M. Vore MDR1 substrates/modulators protect against beta-estradiol-17beta-d-glucuronide cholestasis in rat liver Cancer Res. 56 21 1996 4992 4997
100. Y. Shitara, T. Itoh, H. Sato, A.P. Li, and Y. Sugiyama Inhibition of transporter-mediated uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A J. Pharmacol. Exp. Ther. 304 2003 610 616
101. T. Hatanaka Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events Clin. Pharmacokinet. 39 6 2000 397 412
102. C.D. Scripture, and J.A. Pieper Clinical pharmacokinetics of fluvastatin Clin. Pharmacokinet. 40 4 2001 263 281
103. M. Ohtawa, N. Masuda, I. Akasaka, A. Nakashima, K. Ochiai, and M. Moriyasu Cellular uptake of fluvastatin, an inhibitor of HMG-CoA reductase, by rat cultured hepatocytes and human aortic endothelial cells Br. J. Clin. Pharmacol. 47 4 1999 383 389